Evidence map›Paper›PMID 42037337›Full record

ArticleSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi2026

[A protein-ligand binding affinity prediction model integrating multi-scale interaction features].

Hui Liu, Lixin Yan, Sushan Wang, Jiansheng Peng

Abstract readEnglish Abstract
In one paragraph

Article in Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hui LiuSchool of Computer Science and Technology, Dalian University of Technology, Dalian, Liaoning 116081, P. R. China.
Lixin YanSchool of Computer Science and Technology, Dalian University of Technology, Dalian, Liaoning 116081, P. R. China.
Sushan WangSchool of Computer Science and Technology, Dalian University of Technology, Dalian, Liaoning 116081, P. R. China.
Jiansheng PengSchool of Artificial Intelligence and Manufacturing, Hechi University, Yizhou, Guangxi 546300, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein-ligand binding affinity prediction is critical for drug development, where rapid and accurate assessment of drug-target binding remains a key challenge. Deep learning-based modeling provides a more efficient and scalable solution compared to traditional experimental approaches. This paper proposes a multi-scale interaction feature fusion model for protein-ligand binding affinity prediction, named the multi-scale binding affinity predictor (MSBind). The MSBind model employed multiple attention mechanisms to extract both global and local interaction features between the protein-ligand complex. By jointly modeling this multi-scale information, it ultimately enhanced the model's predictive performance. Experimental results showed that on the PDBbind v2016 core dataset, the root mean square error of MSBind was only 1.23, which was significantly lower than the baselines, demonstrating superior predictive accuracy. Furthermore, dimensionality reduction visualization of the extracted interaction features provided additional validation of the interpretability and effectiveness of MSBind. In summary, by integrating multi-scale interaction features, MSBind provides a high-performance solution for protein-ligand binding affinity prediction.

Indexed as

Deep LearningProteinsDrug DesignLigandsPrediction AlgorithmsProtein BindingLigandsProteinsAttention mechanismBinding affinity predictionDeep learningDrug designFeature fusion

Identifiers

PMID42037337
PMCPMC13112214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.